RISKS FROM OFF-LABEL PROMOTIONS GROWING, EXPERTS SAY

Drug Industry Daily
KEYWORDS Advertising / HHS
A A

Off-label promotion, long a target of FDA enforcement activities under the Food, Drug and Cosmetic Act, has been garnering increased attention as a potential violation of the False Claims Act — with far greater financial consequences — according to healthcare compliance experts.

To View This Article:

Login

Subscribe To Drug Industry Daily